We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Missing Molecule Triggers Ovary Tumors

By Biotechdaily staff writers
Posted on 29 Jun 2005
A missing receptor molecule has been found to be a key factor in the growth of human ovary tumors. More...


This unexpected connection has now been confirmed by researchers at the Medical University of Vienna (Austria), who published their findings in the June 15, 2005, issue of the journal Molecular Cancer Research. The team also found out the possible genetic reason why the receptor molecule, which is a significant factor in controlling cell growth, is missing.

Programmed cell death, known as apoptosis, brings about the controlled death of single cells, if this proves to be beneficial for the entire organism. If this self-protective mechanism does not function correctly, then the destructive cells can grow unchecked. The investigators have now been able to ascertain that programmed cell death does not function in the cells of specific tumors in the ovaries, not because the starting signal is missing, but because this signal cannot be received by the cell.

This discovery demonstrated that these cells are missing a receptor molecule called DR4. DR4 is responsible for receiving the signal molecule tumor necrosis factor-related apoptosis inducing ligand (TRIAL), which triggers apoptosis in these cells.

"To begin with it was not evident what was missing in the signal transmission. The signal or the receptor molecule? To answer this question, we examined 10 different ovarian cancer cell lines. In doing this we found out that 40% of these specimens contained none or only a few DR4 receptor molecules,” explained Prof. Krainer. It was confirmed in additional testing that these cells respond poorly to TRIAL. This confirms that the missing receptor and not the missing signal can considerably contribute to tumor growth.

Additional assessment validated why there was such a small proportion of receptors. "There can be two reasons for the loss of a receptor molecule like DR4. Firstly, the responsible gene could have been lost or damaged. Secondly, this gene could have been modified in a way which would prevent it from functioning,” stated Prof. Krainer. It proved to be precisely the latter. Prof. Krainer and his coworkers discovered that in 75% of the specimens containing only a few DR4 receptors, the responsible gene was altered. Some components of this gene were modified by attaching methyl groups. Methylation is a typical process in which cells silence genes, but in the affected tumor cells, it noticeably occurs at the wrong time.

To conclude their study, Prof. Krainer and his coworkers retested their results. Their findings were validated by evaluating 36 different tumor tissues taken directly from patients. In comparison, these cells signify the real causes of disease much better than cell cultures typically used for experimental research. It was determined that in 20% of the tissues studied, the gene responsible for DR4 was methylated to a higher extent and DR4 was missing.

This research provides insights for future treatment through the significant finding that the methylation of the gene for DR4 can contribute to the formation of tumor formation. These therapies could manipulate the faulty signal transfer system, DR4-TRAIL, to make cancer cells return to the originally programmed cell death.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.